FDA authorization covers platinum-resistant disease after 1–3 prior lines, with mandatory prior bevacizumab exposure, ...

The approval is based on the results of Corcept’s Phase 3 ROSELLA trial, which showed improvements in both progression-free survival and overall survival. ・The approval covers adults with ...

The FDA has approved relacorilant (Lifyorli) in combination with nab-paclitaxel for the treatment of patients with platinum-resistant ovarian cancer. 1. The NDA submission was bas ...

FDA approval of Lifyorli plus nab-paclitaxel offers a new option for platinum-resistant epithelial ovarian cancer after 1 to 3 prior systemic regimens.

JUST over a decade ago they were the three shooting stars of the indigenous art world, the leading lights of the Lockhart River "art gang" ...